In summary, activating the SHH pathway through mutations in the RAS/BRAF/MEK pathway and the presence of paracrine factors in the interstitial space of thyroid cancer cells can enhance GLI1 expression and activity. The gene discussed is GLI1; the disease is thyroid gland carcinoma.